"L’Institut du Cancer de Montpellier (ICM) est le centre de référence en Occitanie-Est, reconnu au niveau national pour son expertise et son innovation dans la prise en charge et le traitement des patients atteints de cancers : cancer du sein, cancers digestifs (colon, rectum, pancréas…), cancers gynécologiques (col de l’utérus, ovaires…), cancer de la prostate, cancer du poumon, sarcomes, cancer ORL... La prise en charge et l’accompagnement des patients atteints de cancer à Montpellier et dans toute la région est assurée par des équipes médicales pluridisciplinaires spécialisées. Il regroupe des unités de soins, de prévention, de recherche clinique, translationnelle et fondamentale en cancérologie. L’ICM fait partie du réseau UNICANCER."

During the past decade, ICM; Medecine B3 conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "ICM; Medecine B3" are "Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers" (1 trials) and "Breast Cancer" (1 trials). Many other conditions were trialed in "ICM; Medecine B3" in a lesser frequency.

Most popular intervention types in "ICM; Medecine B3" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody" (1 trials), "Gemcitabine" (1 trials), "Ipatasertib" (1 trials), "Paclitaxel" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "ICM; Medecine B3" are 2 trials for "All" genders.

Currently, there are NaN active trials in "ICM; Medecine B3". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in ICM; Medecine B3, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in ICM; Medecine B3, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".